Gilead Sciences, Inc. (GILD) Expected to Post Quarterly Sales of $5.38 Billion

Equities analysts predict that Gilead Sciences, Inc. (NASDAQ:GILD) will report sales of $5.38 billion for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Gilead Sciences’ earnings. The lowest sales estimate is $5.20 billion and the highest is $5.68 billion. Gilead Sciences reported sales of $6.51 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 17.4%. The company is expected to announce its next quarterly earnings report on Thursday, October 25th.

On average, analysts expect that Gilead Sciences will report full-year sales of $21.58 billion for the current year, with estimates ranging from $20.91 billion to $22.34 billion. For the next financial year, analysts forecast that the firm will post sales of $21.76 billion per share, with estimates ranging from $19.75 billion to $25.41 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The firm had revenue of $5.65 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the business posted $2.56 earnings per share. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis.

Several equities research analysts have weighed in on the company. Morgan Stanley increased their target price on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 26th. Barclays dropped their target price on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. Leerink Swann set a $72.00 target price on Gilead Sciences and gave the stock a “market perform” rating in a research report on Wednesday, May 2nd. Raymond James assumed coverage on Gilead Sciences in a research report on Thursday, June 28th. They issued a “strong-buy” rating and a $93.00 target price on the stock. Finally, BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Twelve research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $88.00.

Shares of Gilead Sciences opened at $76.73 on Friday, according to Marketbeat Ratings. Gilead Sciences has a 1-year low of $64.27 and a 1-year high of $89.54. The company has a current ratio of 3.00, a quick ratio of 3.23 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $99.70 billion, a price-to-earnings ratio of 8.96, a P/E/G ratio of -5.86 and a beta of 1.03.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend is Thursday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In other news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $68.13, for a total transaction of $3,406,500.00. Following the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $209,006,625.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 150,000 shares of company stock worth $10,839,500 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Griffin Asset Management Inc. grew its holdings in Gilead Sciences by 2.5% during the fourth quarter. Griffin Asset Management Inc. now owns 27,160 shares of the biopharmaceutical company’s stock worth $1,946,000 after acquiring an additional 650 shares during the period. Tompkins Financial Corp grew its holdings in Gilead Sciences by 4.4% during the second quarter. Tompkins Financial Corp now owns 15,479 shares of the biopharmaceutical company’s stock worth $1,096,000 after acquiring an additional 651 shares during the period. Benedict Financial Advisors Inc. grew its holdings in Gilead Sciences by 2.7% during the second quarter. Benedict Financial Advisors Inc. now owns 25,473 shares of the biopharmaceutical company’s stock worth $1,804,000 after acquiring an additional 673 shares during the period. Resource Management LLC grew its holdings in Gilead Sciences by 6.7% during the second quarter. Resource Management LLC now owns 10,688 shares of the biopharmaceutical company’s stock worth $757,000 after acquiring an additional 674 shares during the period. Finally, Jolley Asset Management LLC grew its holdings in Gilead Sciences by 1.3% during the second quarter. Jolley Asset Management LLC now owns 54,746 shares of the biopharmaceutical company’s stock worth $3,878,000 after acquiring an additional 678 shares during the period. 77.59% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Read More: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply